HT screens for the disruption of the T cell receptor CD3 interface
HT screens for the disruption of the T cell receptor CD3 interface
批准号:
8158938
负责人:
Luc Teyton
金额:
$56.85万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2014-07-31
关键词:
AddressAdverse effectsAffectAffinityAnimal ExperimentsAnimalsAntibodiesAntigen-Presenting CellsAutoimmunityBasic ScienceBindingBiochemistryBiologicalBiological AssayBiologyBiophysicsBlood CellsCD3 AntigensCell CycleCell Surface ReceptorsCell surfaceCellsCellular ImmunologyCellular biologyChemicalsChemistryChronicClinicalCommunicable DiseasesCommunicationComplexComputer-Aided DesignCyclosporineCysteineDevelopmentDiseaseEducational process of instructingExhibitsExtracellular DomainFamilyFluorescence PolarizationFundingGoalsHealthcare SystemsHumanImmune responseImmunityImmunologic AdjuvantsImmunologyImmunomodulatorsImmunosuppressionImmunosuppressive AgentsIn VitroInfectionInjection of therapeutic agentInstitutesIntravenousKnowledgeLabelLaboratoriesLeadLife ExpectancyMHC Class I GenesMHC Class II GenesMaintenanceMajor Histocompatibility ComplexMalignant NeoplasmsMasksMedicalMedicineMetabolic PathwayMinorMixed Lymphocyte Culture TestMolecularMusNeoplasmsNucleosidesOrganPeptidesPharmaceutical PreparationsPhaseProcessPropertyQuality of lifeRecombinantsRegimenScreening procedureSeriesSideSignal TransductionSpecialistStagingSteroidsSurfaceSystemT-Cell ActivationT-Cell Immunologic SpecificityT-Cell ReceptorT-LymphocyteTCR ActivationTechnologyTestingTherapeuticToxic effectTranslatingTranslational ResearchTranslationsTransplantationUnited States National Institutes of HealthWorkbasecombatcostdosageflexibilityfluorophoregraft vs host diseasehigh throughput screeninghigh throughput technologyimmunoregulationmeetingsmutantnovel therapeuticsprogramsreceptor bindingsmall moleculestructural biologysuccesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Our project is directly responsive to the program objectives by applying high throughput technologies to isolate small molecules capable of disrupting or modifying the communication between the idiotypic T cell receptor (TCR) and CD3, its obligate signaling partner. Structural and biophysical studies have taught us that the TCR/CD3 interaction was of very low affinity and very sensitive to minor alterations, making it a perfect target for small molecules development. We have created and optimized a fluorescence polarization assay amenable to high throughput screen using recombinant TCR molecules labeled with fluorophore on single cysteine mutants. A proof of concept campaign isolated 6 compounds that showed specificity for TCR binding and were capable of disrupting specifically the TCR/CD3 communication of T cells without affecting T cells signaling. All 6 hits were inhibiting T cell signaling of both MHC class I- and MHC class II-restricted T cells and as such could be categorized as immunosuppressive compounds. Our goals are to identify chemical probes that will allow us to further our basic knowledge of T cell activation and to discover, in that same process, new families of immunomodulators. Indeed, new immunosuppressive drugs are much needed in the field of transplantation and autoimmunity, because of the toxicity of the current treatments. Because of the strategy that we have developed, it is also possible that some chemical fragments that we will isolate, will exhibit immunostimulatory properties. This class of drugs, e.g. general immunostimulants, does not exist yet and would fill a huge gap to combat the immunosuppression of cancer and chronic infectious diseases. Our project illustrates the capabilities of integration that our institute offers by having side-by-side specialists in chemistry, structural biology, biophysics, chemical biology, cellular immunology and animal immunology working together towards a clearly defined goal of translating basic science into the development of new therapeutics.
PUBLIC HEALTH RELEVANCE: High throughput screening using recombinant molecules will be used to discover new families of molecules capable of suppressing or enhancing immune responses. The proof of concept has already been established for immunosuppressive compounds. This project that translates fundamental aspects of T cell biology into the discovery of new drugs has the potential of having a major impact in medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular basis of glycan recognition by T and B cells
-
批准号:10549648
-
项目类别:
-
资助金额:$45.42万
-
财政年份:2023
-
负责人:Luc Teyton
-
依托单位:
Administrative Core
-
批准号:10549641
-
项目类别:
-
资助金额:$3.87万
-
财政年份:2023
-
负责人:Luc Teyton
-
依托单位:
Antibody Core
-
批准号:10549643
-
项目类别:
-
资助金额:$19.46万
-
财政年份:2023
-
负责人:Luc Teyton
-
依托单位:
Leveraging Human iPSC-derived beta-cells to Probe Antigen Specificity of Anti-islet Memory T Cells in T1D
-
批准号:10589556
-
项目类别:
-
资助金额:$76.25万
-
财政年份:2023
-
负责人:Luc Teyton
-
依托单位:
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
-
批准号:10549640
-
项目类别:
-
资助金额:$202.5万
-
财政年份:2023
-
负责人:Luc Teyton
-
依托单位:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
-
批准号:10599324
-
项目类别:
-
资助金额:$67.81万
-
财政年份:2021
-
负责人:Luc Teyton
-
依托单位:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
-
批准号:10218993
-
项目类别:
-
资助金额:$69.98万
-
财政年份:2021
-
负责人:Luc Teyton
-
依托单位:
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
-
批准号:10397167
-
项目类别:
-
资助金额:$67.81万
-
财政年份:2021
-
负责人:Luc Teyton
-
依托单位:
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis
-
批准号:10362605
-
项目类别:
-
资助金额:$78.85万
-
财政年份:2019
-
负责人:Luc Teyton
-
依托单位:
Early diagnosis and mechanistic studies of type 1 diabetes using single cell analysis
-
批准号:9884757
-
项目类别:
-
资助金额:$78.9万
-
财政年份:2019
-
负责人:Luc Teyton
-
依托单位:
Increasing the Social Science Impact of Biomedical Research
-
批准号:10089675
-
项目类别:
-
资助金额:$3.41万
-
财政年份:2018
-
负责人:Luc Teyton
-
依托单位:
NRSA Training Core
-
批准号:10159336
-
项目类别:
-
资助金额:$22.24万
-
财政年份:2018
-
负责人:Luc Teyton
-
依托单位:
NRSA Training Core
-
批准号:10401472
-
项目类别:
-
资助金额:$24.2万
-
财政年份:2018
-
负责人:Luc Teyton
-
依托单位:
Development of the Next Generation of Conjugate Vaccines
-
批准号:9750619
-
项目类别:
-
资助金额:$84.64万
-
财政年份:2018
-
负责人:Luc Teyton
-
依托单位:
Development of the Next Generation of Conjugate Vaccines
-
批准号:10176386
-
项目类别:
-
资助金额:$84.35万
-
财政年份:2018
-
负责人:Luc Teyton
-
依托单位:
BioMark
-
批准号:8446911
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2013
-
负责人:Luc Teyton
-
依托单位:
Molecular Pharmacology of NKT Cell Agonists
-
批准号:8663832
-
项目类别:
-
资助金额:$71.78万
-
财政年份:2013
-
负责人:Luc Teyton
-
依托单位:
Molecular Pharmacology of NKT Cell Agonists
-
批准号:8577662
-
项目类别:
-
资助金额:$69.71万
-
财政年份:2013
-
负责人:Luc Teyton
-
依托单位:
Molecular Pharmacology of NKT Cell Agonists
-
批准号:8850805
-
项目类别:
-
资助金额:$71.78万
-
财政年份:2013
-
负责人:Luc Teyton
-
依托单位:
Molecular Pharmacology of NKT Cell Agonists
-
批准号:9065492
-
项目类别:
-
资助金额:$72.73万
-
财政年份:2013
-
负责人:Luc Teyton
-
依托单位:
海外基金